Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
Kim Henriksen, Inger Byrjalsen, Per Qvist, Henning Beck-Nielsen, Gitte Hansen, Bente J Riis, Hans Perrild, Ole Lander Svendsen, Jeppe Gram, Morten A Karsdal, Claus Christiansen, BALLET Trial Investigators
Dive into the research topics of 'Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy'. Together they form a unique fingerprint.